NEW YORK, June 30, 2017 /PRNewswire/ --To Acquire Sinovac Biotech (Nasnaq: SVA) Sinobioway Consortium Raises Its Purchase Price To $8 Per Share.
On the evening
Just over 24 hours after the announcement above, Sinobioway Consortium ("Consortium B") rapidly submitted to Sinovac's Board of Director and the Special Committee a "Restate Offer" and raised the consideration for privatized acquisition to $8 per share, which is 14.3% higher than the consideration offered in the "Amalgamation Agreement."
(To find more information, please see Consortium B's announcement http://www.cninfo.com.cn/finalpage/2017-06-28/1203656646.PDF)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/update-to-acquire-sinovac-biotech-nasnaq-sva-sinobioway-consortium-raises-its-purchase-price-to-8-per-share-300482679.html
SOURCE Shandong Sinobioway Biomedicine Co., Ltd
Subscribe to our Free Newsletters!
Appendicitis in children produces symptoms of abdominal pain and swelling, nausea, vomiting and ...